AR006892A1 - Uso de formas del acido hialuronico (ha) para el tratamiento del cancer - Google Patents
Uso de formas del acido hialuronico (ha) para el tratamiento del cancerInfo
- Publication number
- AR006892A1 AR006892A1 ARP970101754A ARP970101754A AR006892A1 AR 006892 A1 AR006892 A1 AR 006892A1 AR P970101754 A ARP970101754 A AR P970101754A AR P970101754 A ARP970101754 A AR P970101754A AR 006892 A1 AR006892 A1 AR 006892A1
- Authority
- AR
- Argentina
- Prior art keywords
- hyaluronic acid
- treatment
- cancer
- forms
- diluent
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 4
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se provee un método para el tratamiento del cáncer que comprende la administración por vía oral o sistémica (preferentemente intravenosa) de unacantidad dosificada efectiva de una forma del ácido hialurónico seleccionado del grupo que consiste de ácido hialurónico y las salesfarmacéuticamente aceptables del mismo como único agente terapéutico activo, en un diluyente, en cantidades tales y durante el tiempo suficientes como parapermitir un tratamiento exitoso del cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002175282A CA2175282A1 (en) | 1996-04-29 | 1996-04-29 | Use of forms of hyaluronic acid (ha) for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006892A1 true AR006892A1 (es) | 1999-09-29 |
Family
ID=4158095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101754A AR006892A1 (es) | 1996-04-29 | 1997-04-29 | Uso de formas del acido hialuronico (ha) para el tratamiento del cancer |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR006892A1 (es) |
| AU (1) | AU2564497A (es) |
| CA (1) | CA2175282A1 (es) |
| WO (1) | WO1997040841A1 (es) |
| ZA (1) | ZA973622B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888984A (en) * | 1994-05-12 | 1999-03-30 | Dermal Research Laboratories, Inc. | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| NZ512676A (en) | 1999-01-13 | 2003-01-31 | Meditech Res Ltd | A composition and method for the enhancement of the efficacy of drugs |
| CA2361268C (en) | 1999-02-01 | 2014-06-10 | Dermal Research Laboratories, Inc. | A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| AU3886600A (en) * | 1999-03-15 | 2000-10-04 | Trustees Of Boston University | Angiogenesis inhibition |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| AU760404B2 (en) * | 2000-07-14 | 2003-05-15 | Alchemia Oncology Pty Limited | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| US7879824B2 (en) | 2001-07-31 | 2011-02-01 | Dermal Research Laboratories, Inc. | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| CA2417867C (en) * | 2000-07-31 | 2012-09-11 | Dermal Research Laboratories, Inc. | Methods of preventing or treating diseases and conditions using complex carbohydrates |
| AU2002325635C1 (en) * | 2001-08-27 | 2008-09-25 | Alchemia Oncology Pty Limited | Improved therapeutic protocols |
| US20050042303A1 (en) * | 2001-08-27 | 2005-02-24 | Brown Tracey Jean | Therapeutic protocols |
| ITPD20020271A1 (it) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| AU2006274509B2 (en) | 2005-07-27 | 2012-01-19 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| BRPI0615619A2 (pt) | 2005-09-07 | 2011-05-24 | Alchemia Oncology Pty Ltd | composições terapêuticas que compreendem hialuronana e anticorpos terapêuticos bem como métodos de tratamento |
| US9375447B2 (en) * | 2013-03-14 | 2016-06-28 | National Cheng Kung University | Modified hyaluronan and uses thereof in cancer treatment |
| CN105311051A (zh) | 2014-05-26 | 2016-02-10 | 陈松源 | 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117A (ja) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | ムコ多糖系癌転移抑制剤 |
| US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
| CA2067211C (en) * | 1990-07-24 | 2004-06-15 | Katsukiyo Sakurai | Phospholipid- or lipid-linked glycosaminoglycan, process for producing the same and metastasis inhibitor |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| WO1994020115A2 (en) * | 1993-03-10 | 1994-09-15 | Miles, Inc. | Hyaluronic acid used as a cancer treatment |
-
1996
- 1996-04-29 CA CA002175282A patent/CA2175282A1/en not_active Abandoned
-
1997
- 1997-04-25 ZA ZA9703622A patent/ZA973622B/xx unknown
- 1997-04-28 WO PCT/CA1997/000283 patent/WO1997040841A1/en not_active Ceased
- 1997-04-28 AU AU25644/97A patent/AU2564497A/en not_active Abandoned
- 1997-04-29 AR ARP970101754A patent/AR006892A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2564497A (en) | 1997-11-19 |
| CA2175282A1 (en) | 1997-10-30 |
| ZA973622B (en) | 1997-11-25 |
| WO1997040841A1 (en) | 1997-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006892A1 (es) | Uso de formas del acido hialuronico (ha) para el tratamiento del cancer | |
| ES2074124T3 (es) | Composicion en forma de una espuma que contiene acido 5-aminosalicilico para administracion intra-rectal. | |
| CR6656A (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| MXPA01003182A (es) | Sistema de liberacion controlada de agentes antifungicos y queratoliticos para el tratamiento local de las infecciones fungicas de la una y los tejidos circundantes. | |
| ES2094539T3 (es) | Preparacion farmaceutica y procedimiento para su preparacion. | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| CO5060522A1 (es) | Administracion de un agente activo en aerosol | |
| AR020760A1 (es) | DISPOSITIVO PARA CONTROLAR LA ADMINISTRACIoN DE UN AGENTE ACTIVO EN AEROSOL EN LOS PULMONES DE UN PACIENTE HUMANO | |
| ES2077530B1 (es) | Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales. | |
| ES2082288T3 (es) | Composiciones terapeuticas para administracion intranasal de ketorolaco. | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
| PE28397A1 (es) | Soluciones salinas no inorganicas para administracion endonasal | |
| BR0109672A (pt) | Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente | |
| AR032151A1 (es) | Uso de un farmaco anti-angiogenico en conjunto con un agente fotosensible para la preparacion de un medicamento para el tratamiento fotodinamico mejorado de la neovasculatura indeseada | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| ES2125696T3 (es) | Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales. | |
| ECSP045110A (es) | Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción | |
| AR002743A1 (es) | Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis. | |
| AR002027A1 (es) | Formulaciones transdermicas y proceso para prepararlas. | |
| ES2099649T3 (es) | Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida. | |
| DK1194109T3 (da) | Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf | |
| CO5271647A1 (es) | Metodo para prevenir la diarrea | |
| EE200200549A (et) | Jagatud doosi teraapia veresooni kahjustava aktiivsusega | |
| AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple |